GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » EV-to-FCF
中文

GlucoTrack (GlucoTrack) EV-to-FCF

: -3.13 (As of Today)
View and export this data going back to 2000. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GlucoTrack's Enterprise Value is $20.51 Mil. GlucoTrack's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.56 Mil. Therefore, GlucoTrack's EV-to-FCF for today is -3.13.

The historical rank and industry rank for GlucoTrack's EV-to-FCF or its related term are showing as below:

GCTK' s EV-to-FCF Range Over the Past 10 Years
Min: -31.43   Med: -5.27   Max: 2.28
Current: -2.66

During the past 13 years, the highest EV-to-FCF of GlucoTrack was 2.28. The lowest was -31.43. And the median was -5.27.

GCTK's EV-to-FCF is ranked worse than
100% of 371 companies
in the Medical Devices & Instruments industry
Industry Median: 25.8 vs GCTK: -2.66

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), GlucoTrack's stock price is $0.84. GlucoTrack's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.370. Therefore, GlucoTrack's PE Ratio for today is At Loss.


GlucoTrack EV-to-FCF Historical Data

The historical data trend for GlucoTrack's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.90 -17.39 -15.53 -5.29 -0.18

GlucoTrack Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.29 -1.18 0.36 0.24 -0.18

Competitive Comparison

For the Medical Instruments & Supplies subindustry, GlucoTrack's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlucoTrack EV-to-FCF Distribution

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GlucoTrack's EV-to-FCF falls into.



GlucoTrack EV-to-FCF Calculation

GlucoTrack's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=20.507/-6.558
=-3.13

GlucoTrack's current Enterprise Value is $20.51 Mil.
GlucoTrack's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlucoTrack  (NAS:GCTK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

GlucoTrack's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.84/-0.370
=At Loss

GlucoTrack's share price for today is $0.84.
GlucoTrack's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.370.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GlucoTrack EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GlucoTrack's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GlucoTrack (GlucoTrack) Business Description

Traded in Other Exchanges
N/A
Address
301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It also focuses on developing a wireless module for transmission of measurement data captured by the GlucoTrack model DF-F to a cloud-based server.
Executives
James S Cardwell officer: Chief Financial Officer CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter director 301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig director 301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps director C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
Drew Sycoff director C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
David Podwalski officer: Chief Commercial Officer 19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham director, officer: Chief Executive Officer 19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun officer: Chief Financial Officer 39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff director 1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Angela Strand Boydston director C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Leslie Seff director PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Eran Hertz officer: Chief Financial Officer C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich director C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100